Diagnosis and Treatment of Infections due to Mycobacterium avium Complex

 

 Buy Article Permissions and Reprints

ABSTRACT

Mycobacterium avium complex (MAC) consists of nontuberculous mycobacteria that cause disease in immunocompromised and immunocompetent hosts. The organisms are ubiquitous in the environment, and acquisition occurs through ingestion or inhalation of aerosols from soil, water, or biofilms. Disease may manifest as disseminated infection, soft tissue infection, chronic pneumonia, or hypersensitivity pneumonitis. Nontuberculous mycobacteria are increasingly associated with pulmonary disease, with MAC being the most common nontuberculous mycobacteria to cause pulmonary disease in the United States. Pulmonary symptoms, nodular or cavitary opacities on a chest radiograph or high-resolution computed tomographic scan with multifocal bronchiectasis and multiple small nodules, plus positive culture results from two sputum specimens or one bronchoscopic specimen are consistent with MAC pulmonary disease. Treatment consists of a macrolide, rifamycin, and ethambutol given three times weekly for noncavitary disease and daily with or without an aminoglycoside for cavitary disease.

REFERENCES

• 1 Turenne C Y, Wallace Jr R, Behr M A. Mycobacterium avium in the postgenomic era.  Clin Microbiol Rev. 2007;  20 205-229
  CrossrefPubMedGoogle Scholar
• 2 Falkinham III J O. Nontuberculous mycobacteria in the environment.  Clin Chest Med. 2002;  23 529-551
  CrossrefPubMedGoogle Scholar
• 3 Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria.  Clin Chest Med. 2002;  23 553-567
  CrossrefPubMedGoogle Scholar
• 4 Khan K, Wang J, Marras T K. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades.  Am J Respir Crit Care Med. 2007;  176 306-313
  CrossrefPubMedGoogle Scholar
• 5 Marras T K, Chedore P, Ying A M, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.  Thorax. 2007;  62 661-666
  CrossrefPubMedGoogle Scholar
• 6 Griffith D E, Aksamit T, Brown-Elliott B A et al.. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
  CrossrefPubMedGoogle Scholar
• 7 Pasteur M C, Helliwell S M, Houghton S J et al.. An investigation into causative factors in patients with bronchiectasis.  Am J Respir Crit Care Med. 2000;  162(4 Pt 1) 1277-1284
  CrossrefPubMedGoogle Scholar
• 8 Field S K, Fisher D, Cowie R L. Mycobacterium avium complex pulmonary disease in patients without HIV infection.  Chest. 2004;  126 566-581
  CrossrefPubMedGoogle Scholar
• 9 Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin J P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.  Chest. 1995;  107 1035-1040
  PubMedGoogle Scholar
• 10 Wallace Jr R J, Brown B A, Griffith D E et al.. Initial clarithromycin monotherapy for Mycobacterium avium–intracellulare complex lung disease.  Am J Respir Crit Care Med. 1994;  149 1335-1341
  CrossrefPubMedGoogle Scholar
• 11 Griffith D E, Brown B A, Girard W M, Murphy D T, Wallace Jr R J. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 983-989
  PubMedGoogle Scholar
• 12 Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.  J Infect Chemother. 2006;  12 195-202
  CrossrefPubMedGoogle Scholar
• 13 Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan—including a follow-up study.  Respiration. 2007;  74 394-400
  CrossrefPubMedGoogle Scholar
• 14 Kuwabara K, Tsuchiya T. Clinical features and treatment history of clarithromycin resistance in M. avium–intracellulare complex pulmonary disease patients [in Japanese].  Nihon Kokyuki Gakkai Zasshi. 2007;  45(8) 587-592
  PubMedGoogle Scholar
• 15 Griffith D E, Brown-Elliott B A, Langsjoen B et al.. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.  Am J Respir Crit Care Med. 2006;  174 928-934
  CrossrefPubMedGoogle Scholar
• 16 Kohno Y, Ohno H, Miyazaki Y et al.. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.  Antimicrob Agents Chemother. 2007;  51 4071-4076
  CrossrefPubMedGoogle Scholar
• 16a Kasperbauer S, Wilson S E, Graham J J, Heifets L, Daley C. Fluoroquinolone susceptibility in non-tuberculous mycobacteria. Presented at: The American Thoracic Society International Conference May 23, 2007 San Francisco, CA; Abstract p. 971
  Google Scholar
• 17 Griffith D E, Brown B A, Girard W M, Griffith B E, Couch L A, Wallace Jr R J. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.  Clin Infect Dis. 2001;  32 1547-1553
  CrossrefPubMedGoogle Scholar
• 18 Griffith D E, Brown B A, Cegielski P, Murphy D T, Wallace Jr R J. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.  Clin Infect Dis. 2000;  30 288-292
  CrossrefPubMedGoogle Scholar
• 19 Lam P K, Griffith D E, Aksamit T R et al.. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.  Am J Respir Crit Care Med. 2006;  173 1283-1289
  CrossrefPubMedGoogle Scholar
• 20 Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease.  Respir Med. 2007;  101 130-138
  CrossrefPubMedGoogle Scholar
• 21 Jenkins P A, Campbell I A, Banks J, Gelder C M, Prescott R J, Smith A P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.  Thorax. 2008;  63 627-634
  CrossrefPubMedGoogle Scholar
• 22 Kuroishi S, Nakamura Y, Hayakawa H et al.. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings.  Eur Respir J. 2008;  32 147-152
  CrossrefPubMedGoogle Scholar
• 23 Horsburgh Jr C R. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 1332-1338
  PubMedGoogle Scholar
• 24 Chin D P, Hopewell P C, Yajko D M et al.. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection.  J Infect Dis. 1994;  169 289-295
  PubMedGoogle Scholar
• 25 von Reyn C F, Maslow J N, Barber T W, Falkinham III J O, Arbeit R D. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS.  Lancet. 1994;  343 1137-1141
  CrossrefPubMedGoogle Scholar
• 26 Benson C A. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome.  Clin Infect Dis. 1994;  18(Suppl 3) S218-S222
  PubMedGoogle Scholar
• 27 Benson C A, Kaplan J E, Masur H, Pau A, Holmes K K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.  MMWR Recomm Rep. 2004;  53(RR-15) 1-112
  PubMedGoogle Scholar
• 28 Benson C A, Williams P L, Currier J S et al.. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.  Clin Infect Dis. 2003;  37 1234-1243
  CrossrefPubMedGoogle Scholar
• 29 Gordin F M, Sullam P M, Shafran S D et al.. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex.  Clin Infect Dis. 1999;  28 1080-1085
  CrossrefPubMedGoogle Scholar
• 30 Corti M, Villafane M F, Ambroggi M, Sawicki M, Gancedo E. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy.  Rev Inst Med Trop Sao Paulo. 2007;  49 267-270
  PubMedGoogle Scholar
• 31 Phillips P, Bonner S, Gataric N et al.. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.  Clin Infect Dis. 2005;  41 1483-1497
  CrossrefPubMedGoogle Scholar
• 32 Shelburne III S A, Hamill R J. The immune reconstitution inflammatory syndrome.  AIDS Rev. 2003;  5 67-79
  PubMedGoogle Scholar
• 33 Salvana E M, Cooper G S, Salata R A. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients.  J Infect. 2007;  55 484-487
  CrossrefPubMedGoogle Scholar
• 34 Olsen R J, Cernoch P L, Land G A. Mycobacterial synovitis caused by slow-growing nonchromogenic species: eighteen cases and a review of the literature.  Arch Pathol Lab Med. 2006;  130 783-791
  PubMedGoogle Scholar
• 35 Hellinger W C, Smilack J D, Greider Jr J L et al.. Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist.  Clin Infect Dis. 1995;  21 65-69
  PubMedGoogle Scholar
• 36 Maltezou H C, Spyridis P, Kafetzis D A. Nontuberculous mycobacterial lymphadenitis in children.  Pediatr Infect Dis J. 1999;  18 968-970
  CrossrefPubMedGoogle Scholar
• 37 Liao C H, Lai C C, Ding L W et al.. Skin and soft tissue infection caused by non-tuberculous mycobacteria.  Int J Tuberc Lung Dis. 2007;  11 96-102
  PubMedGoogle Scholar
• 38 Hanak V, Golbin J M, Ryu J H. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis.  Mayo Clin Proc. 2007;  82 812-816
  CrossrefPubMedGoogle Scholar
• 39 Marras T K, Wallace Jr R J, Koth L L, Stulbarg M S, Cowl C T, Daley C L. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water.  Chest. 2005;  127 664-671
  CrossrefPubMedGoogle Scholar
• 40 Hartman T E, Jensen E, Tazelaar H D, Hanak V, Ryu J H. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium–intracellulare inhalation: “hot tub lung”.  AJR. 2007;  188 1050-1053
  CrossrefPubMedGoogle Scholar
• 41 Hanak V, Kalra S, Aksamit T R, Hartman T E, Tazelaar H D, Ryu J H. Hot tub lung: presenting features and clinical course of 21 patients.  Respir Med. 2006;  100 610-615
  CrossrefPubMedGoogle Scholar
• 42 Centers for Diseases Control and Prevention . Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria—Ohio, 2001.  JAMA. 2002;  287 3073-3074
  CrossrefPubMedGoogle Scholar
• 43 Centers for Disease Control and Prevention (CDC) . Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria—Ohio, 2001.  MMWR Morb Mortal Wkly Rep. 2002;  51 349-352
  PubMedGoogle Scholar

Shannon H KasperbauerM.D. 

Division of Mycobacterial and Respiratory Infections

National Jewish Health, 1400 Jackson St., Denver, CO 80206

Email: kasperbauers@njc.org